Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
This study has been withdrawn prior to enrollment.
(This study has been withdraw from the IRB. The PI has transferred to another university. The IND was transferred.)
Sponsor:
University of Arkansas
Information provided by:
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00556387
First received: November 9, 2007
Last updated: May 12, 2009
Last verified: May 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the possible effects of an anesthetic agent called Ketamine on the injured brain in children.
The researchers think that it will effect the outcomes of children with these injuries.
| Condition | Intervention | Phase |
|---|---|---|
|
Traumatic Brain Injury |
Drug: saline Drug: Ketamine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Possible Neuroprotective Effects of Ketamine in Children With Severe Traumatic Brain Injury |
Resource links provided by NLM:
Further study details as provided by University of Arkansas:
Primary Outcome Measures:
- To compare clinical, radiological, and neurodevelopmental outcomes between children who receive ketamine vs placebo infusions following traumatic brain injury. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To compare the expression of biomarkers of CNS injury between cases and controls. [ Time Frame: 96 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 1
Placebo Group receiving Saline Infusion.
|
Drug: saline
1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
|
|
Experimental: 2
Case Group receiving Ketamine infusion.
|
Drug: Ketamine
1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
|
Eligibility| Ages Eligible for Study: | 1 Month to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- are 1 month to 16 years of age; AND
- are admitted to the PICU following severe TBI (any GCS 3-8 inclusive) within 8 hours after the injury; AND
- are intubated and ventilated for the management of TBI; AND
- are anticipated to have an indwelling arterial or venous catheter for blood sampling during the first three days of study enrollment; AND
- have an intra-cranial pressure (ICP) monitoring device for management of TBI.
Exclusion Criteria:
- are less than 4 kilograms in weight upon admission
- are less than 1 month of age;
- are greater than 16 years of age;
- have a clinical diagnosis of non-accidental TBI;
- have suffered immersion injury or prolonged hypoxic injury (lasting greater than 10 minutes);
- have a known allergy to ketamine;
- have a planned removal of endotracheal tube or the removal of central venous catheter AND arterial catheter within 72 hours of study enrollment;
- have a current history of neuromuscular disease;
- have a current history of hepatic failure;
- have a current history of glaucoma
- require chronic treatment with anti-epileptic drugs (AEDs) or devices;
- more than 8 hours have elapsed from the time of injury to PICU admission;
- have documentation of a positive pregnancy test at the time of enrollment;
- if there is a lack of commitment to aggressive intensive care therapies (the subject is either on a DNR status due to pre-existing medical condition, or the family decides to withdraw support prior to participation in the study due to other multiple severe injuries and organ failures resulting from the trauma).
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Carole Hamon, Regulatory Affairs Manager, University of Arkansas for Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00556387 History of Changes |
| Other Study ID Numbers: | IRB 86674, 86674 |
| Study First Received: | November 9, 2007 |
| Last Updated: | May 12, 2009 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by University of Arkansas:
|
traumatic brain injury |
Additional relevant MeSH terms:
|
Brain Injuries Brain Diseases Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Ketamine Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013